
Roche has reported contradictory results from two identical Phase III studies of lebrikizumab in severe asthma, with one showing the …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

